#1lumiraDx™ Transforming Community-based Healthcare September 2022 Exhibit 99.1#2Disclaimer FORWARD-LOOKING STATEMENTS All statements other than statements of historical facts contained in this presentation are forward-looking statements. Forward-looking statements may generally be identified by the use of words such as "believe," "may," "will," "estimate," "continue," "antidpate," "intend," "expect," "should," "would," plan," "projed," "forecast." "predict," "potential," "seem," "seek," "future," "outlook," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of other financial and performance metrics, projections of market opportunity and market share, our future results of operations and financial position, business strategy, the Platform, other products, tests, ongoing and planned predinical studies and clinical trials, regulatory submissions and approvals, research and development costs, timing and likelihood of success, as well as plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this presentation, and on the current expectations of the management of Lumira Dx Limited (LumiraDx" or the "Company") and are not predictions of actual performance. These forward- looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions, and such differences may be material. Many actual events and drcumstances are beyond the control of LumiraDx. These forward-looking statements are subject to a number of risks and uncertainties induding our ability to compete in the highly competitive markets in which we operate, and potential adverse effects of this competition; our ability to maintain revenues if our products and services do not achieve and maintain broad market acceptance, or if we are unable to keep pace or adapt to rapidly changing technology, evolving industry standards and changing regulatory environments, uncertainty, downturns and changes in the markets we serve; our expectations regarding the size of the POC market for the Platform, the size of the various addressable markets for certain tests and our ability to penetrate such markets by driving the conversion of healthcare providers' testing needs onto the Platform; our commerdalization strategy, induding our plans to initially focus our sales efforts on large healthcare systems, government organizations and national pharmacy chains that want to deploy comprehensive POC testing across their networks, our strategy on the commercialization of our current and future assays and our ability to launch and obtain regulatory approval for new tests, our ability to increase the installed base of our Instruments, our ability to repay or service our debt obligations and meet the financial covenants related to such debt obligations, our belief that we will be able to drive commercialization of the Platform through the launch of our SARS-CoV-2 antigen and SARS-CoV-2 antibody tests, the willingness of healthcare providers to use a POC system over central lab systems and the rate of adoption of the Platform by healthcare providers and other users, the scalability and commercial viability of our manufacturing methods and processes, especially in light of the anticipated demand for the Platform and our minimum commitments to supply the Instrument and test strips in a timely fashion; our ability to maintain our current relationships, or enter into new relationships, with diagnostics or research and development companies, third party manufacturers and commercial distribution collaborators: our ability to effectively manage our anticipated growth; our ability to rapidly develop and commerdalize diagnostics tests that are accurate and cost-effective; the timing, progress and results of our diagnostic tests, induding statements regarding launch plans and commercialization plans for such tests, all which may be delayed by or halted due to a number of factors, induding the impact of the COVID-19 pandemic and the end of the COVID-19 pandemic; the timing, scope or likelihood of regulatory submissions, filings, approvals, authorizations, certifications, clinical trials or clearances; the priding, coverage and reimbursement of the Instrument and tests, if approved; our ability to enforce our intellectual property rights and to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights and proprietary technology of third parties, developments and projections relating to our competitors and our industry; our ability to attract, motivate and retain qualified employees, induding members of our senior management team; the effects of the COVID-19 pandemic, induding mitigation efforts and economic effects, on any of the foregoing or other aspects of our business or operations, social, economic, and labor instability in the countries in which we or the third parties with whom we engage operate, induding any impact of the current conflict between Russia and Ukraine; our expectations regarding the time during which we will be an emerging growth company under the JOBS Act and a foreign private issuer, the future trading price of our common shares and impact of securities analysts' reports on these prices, our ability to fully derive anticipated benefits from existing or future acquisitions, joint ventures, investments or dispositions, exchange rate fluctuations and volatility in global currency markets, potential adverse tax consequences resulting from the international scope of our operations, corporate structure and financing structure; U.S. tax legislation enacted in 2017, which could materially adversely affect our finandal condition, results of operations and cash flows, increased risks resulting from our international operations and expectations of future expansion of such operations, our ability to comply with various trade restrictions, such as sanctions and export controls, resulting from our international operations, government and agency demand for our products and services and our ability to comply with government contracting regulations, our ability to operate in a litigious environment, and those factors discussed under the header "Risk Factors" in the Annual Report on Form 20-F filed by LumiraDx with the Securities and Exchange Commission, or SEC, on April 13, 2022, in the Form 6-K fled by LumiraDx with the SEC on August 16, 2022, and in other filings made by LumiraDx with the SEC. If any of these risks materialize or LumiraDx's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that LumiraDx presently knows or that LumiraDx currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward- looking statements reflect LumiraDx's expectations, plans or forecasts of future events and views as of the date of this presentation. LumiraDx anticipates that subsequent events and developments will cause LumiraDx's assessments to change. However, while LumiraDx may elect to update these forward-looking statements at some point in the future, LumiraDx specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing LumiraDx's assessments as of any date subsequent to the date of this presentation. Accordingly, undue reliance should not be placed upon the forward-looking statements. LumiraDx has no obligation to update this presentation. INDUSTRY AND MARKET DATA This presentation includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties as well as our own estimates of potential market opportunities. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. LumiraDx believes that these third-party sources and estimates are reliable, but has not independently verified them. LumiraDx's estimates of the potential market opportunities for its Platform indude several key assumptions based on industry knowledge, industry publications, third-party research and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While LumiraDx believes that its own internal assumptions are reasonable, no independent source has verified such assumptions. The industry in which LumiraDx operatesis subject to a high degree of uncertainty and risk due to a variety of important factors that could cause results to differ materially from those expressed in the estimates made by third parties and by LumiraDx USE OF PROJECTIONS This presentation contains projected financial information with respect to LumiraDx, induding, but not limited to, estimated results for fiscal year 2025. Such projected financial information constitutes forward-looking information, and is for illustrative purposes only and should not be relied upon as necessarily being indicative of future results. The assumptions and estimates underlying such finandal forecast information are inherently uncertain and are subject to a wide variety of significant business, economic, competitive and other risks and uncertainties that could cause actual results to differ materially from those contained in the prospective finandal information. See "Forward-Looking Statements paragraph above. Actual results may differ materially from the results contemplated by the financial forecast information contained in this presentation, and the inclusion of such information in this presentation should not be regarded as a representation by any person that the results reflected in such forecasts will be achieved. lumiraDx™ Copyright © 2022 LumiraDx Ltd. All Rights Reserved. Worldwide#3LumiraDx Today: Transforming Community-based Healthcare Next Generation POC(1) Diagnostic Company Large Installed Base with Global Commercial Reach Manufacturing Designed for Scale Broad Menu and Pipeline of Diagnostic Tests Experienced Management Team lumiraDx™ Addressing the current limitations of legacy POC systems by bringing lab-comparable performance to the POC in minutes, a broad menu of tests on a single instrument, and a low cost of ownership 25,000 instruments shipped to 105 countries across primary care, pharmacy, hospital emergency departments, global health, and other settings All current and future POC tests are developed on common strip design, enabling flexible, automated and low-cost manufacturing on a single line. Current manufacturing capacity of 28 million test strips per month Regulatory clearance for 12 tests for use on our Platform, with global TAM of $5B+ (excluding COVID).(2) 50+ assays in three-year roadmap Fourth POC company for founding team. Management team has a successful track record of diagnostic innovation and building / scaling companies in POC (1) "POC" means point of care. (2) Global Total Addressable Market ("TAM"): We estimate each test based on our current assumptions, including (a) the existing marketsizes, (b) central lab market that could move to POC; and (c) expansion of diagnostic testing. Copyright ©2022 Lumirax Ltd. All Rights Reserved. Worldwide#4Ron Zwanziger CEO, Co-Founder, Chairman and Director Tom Quinlan General Manager, Health IT lumiraDx™ Dave Scott, Ph.D. Chief Technology Officer, Co-Founder and Director David Walton, D.M.S. Chief Commercial Officer Dorian LeBlanc, C.P.A. CFO and Vice President, Global Operations Leadership Team Jerry McAleer, Ph.D. Chief Scientist, Co-Founder and Director Peter Scheu President, North American Commercial Operations Pooja Pathak Chief Product Officer Nigel Lindner, Ph.D. Chief Innovation Officer Veronique Ameye Executive Vice President and General Counsel Copyright © 2022 LumiraDx Ltd. All Rights Reserved. Worldwide inverness (Founders) Abbott Baxter UniPath. SPD Swiss Precision Diagnostic Management Experience Omnicom Alere (Founders) Lilly IM Thermo Fisher SCIENTIFIC CORNING Unilever FitLinxx. MediSense® (Founders) & NOVARTIS BIO-RAD Apogent Concateno™ ::DigiTech#5– Sains Cary G Whet SARS-CoV-2 Ag Ultra www B Un SARS-CoV-2 Ag Ultra Pool Company & Market Introduction SARS-CoV-2 Ab SARS-CoV-2 & RSV SARS-CoV-2 & Flu A/B HbAlc D-Dimer INR SMA NT-proBNP Copyright ©2022 LuminaDx Ltd. All Rights Reserved, Worldwide CRP General User Patient Test Rut History Bettings Quality Control Logout TurniraDx#6LumiraDx is focused on transforming community-based healthcare by providing fast, accurate, cost effective and comprehensive diagnostic information to healthcare providers enabling better medical decisions leading to improved outcomes Cumulative Instruments Shipped Strip Manufacturing Capacity / Month Countries served Cumulative Revenue +$750m Cumulated Sales Since 2019 2019 -200 4 Million lumiraDx™ 6 $23M 2020 -8,000 16 Million LumiraDx Overview 27 $162M 2021 -21,000 28 Million 98 $583M LumiraDx currently has 12 tests approved on its Platform, with a pipeline of over 50 tests Q2 2022 -25,000 28 Million 105 $754M Copyright © 2022 LumiraDx Ltd. All Rights Reserved. Worldwide 25k+ Platforms Placed Globally Instrument Placement Locations#7125 100 75 50 25 0 Our Platform and Tests Target All Segments of the Global IVD(1) Market 12 POC Professional Testing lumiraDx™ LumiraDx Targets the Global IVD Market ($B) 64 Central Lab 28 COVID (1) "IVD" mea In Vitro Diagnostics. Source: Industry reports, companyestimates. 13 Self Testing Copyright © 2022 LumiraDx Ltd. All Rights Reserved. Worldwide 117 Total Diagnostic Market is Supported by Numerous Trends Increasing focus on early prevention and diagnostic testing Effort to improve health outcomes for patients, and cost effectiveness for healthcare providers and payers Ageing population in developed market ✓ Increase in disease prevalence Rise of Precision Medicine#8Patient visits Point-of-care (GP, Pharmacy, ER) Sample(s) collected lumiraDx™ Healthcare Systems Need Enhanced Access to Diagnostic Testing Sample packed for transport Sample shipped to central lab Test Performed at Central Lab Lab processes sample Results verified ENNEND Up to -1 Week from Collection to Results Test Performed at POC Sample Processed by POC instrument !! Clinician receives Patient receives results Copyright © 2022 LumiraDx Ltd. All Rights Reserved. Worldwide results Patient receives results Short time between Collection to Results → Enables Faster and more Effective Care * Extended time to diagnosis and treatment selection * Significant logistic requirements * Higher cost to healthcare system Rapid delivery of results and diagnosis Convenient and easily accessible Allows immediate treatment decision (if required) Significant cost efficiencies Improved patient experience#9Current POC Solutions Have Major Limitations The traditional approach to POC test development has limited scalability and has resulted in ineffective, inefficient and costly solutions X Poor clinical performance in areas of high clinical need X High cost of total ownership X Limited test menu lumiraDx™ Coagulation Respiratory Molecular Copyright © 2022 LuminaDx Lit. All Rights Reserved. Worldwide. Respiratory Immunoassay Diabetes, Cardiovascular Diabetes, Inflammation Cardiac, Blood gas, Metabolic#10Current POC Solutions Have Major Limitations (cont'd) Typical Physician Office Lab DAY READ Glucose lumiraDx™ HbA1c Mono (4) Bang | hot megh x Proliferation of instruments * Many different workflows OVER FO ACROSSCO W Flu Flu Copyright © 2022 Lumirax Ltd. All Rights Reserved, Worldwide Strep x Limited clinical performance x Limited test menu per instrument INR Pregnancy Urinalysis 10#11We Have Developed and Commercialized an Innovative, Disruptive Solution for POC Testing Consolidating multiple POC systems onto a single instrument, the LumiraDx Platform is designed to be a one-stop solution to transform diagnostic testing and health outcomes around the world lumiraDx™ SAMPLE Copyright © 2022 LuminaDx Lit. All Rights Reserved. Worldwide. Lab-comparable performance in minutes Broad menu of tests on a single instrument Low cost of ownership 11#12We Have Launched a Broad Menu of Tests with Lab Comparable Performance TAM¹ Market² TAM¹ Market² SARS-CoV-2 Ag INR Test US / EU / JP / BR $500M T EU SARS-CoV-2 Ab Tost Coagulation SARS-CoV-2 Ag PoolTest $12B D-Dimer Tost $700M EU SARS-CoV-2 Ag Utha Test EU CRP Test BOCA Inflammation $300M EU GALLINE SARS-CoV-2 Ag Uttra Pool Test Respiratory & FAR SARS-CON-2 The A/B Ted $1.5-3B EU / JP Diabetes HbAlc Test $1.3B EU Lattia KASV SARS-CoV-2 & RSV Tos! $200-400M EU Cardiovascular Maste NT-proBNP Test $350M EU amira COVID-19 lumiraDx™ (2) Markets with regulatory authorization. Products available in the market or planned to launch in 2022. Copyright ©2022 LuminaDx Ltd. All Rights Reserved. Worldwide $9B EU Enzyme RNA STAR COVID RNA STAR COVID RNA STAR Complete Molecular ■♥ COVID & Flu RNA STAR Complete $12B/$12B/$1B Area Legend Qualitative Immunoassay US / EU Quantitative Immunoassay (1) 2021 Global Total Addressable Market ("TAM"), based on our assumptions, including the (a) existing market sizes, (b) centrallab market that could move to the POC, and (c) expansion of diagnostic testing. COVID TAMs difficult to estimate at present, may overlap with each other. 12#13Our Pipeline Will Support Sustainable Growth Planned Submissions Disease Area and Test Respiratory Coagulation Cardiovascular Diabetes Global Health Inflammation COVID Ultra CRP Flu A/B Ultra RSV Ultra Strep A INR D-Dimer NT-ProBNP HS Troponin BNP Na/K Lipids HbAle TB HIV Viral Load CRP ProcalcHonin Concept Qual Immunoassay Feasibility Development Quant Immunoassay Verification & Validation Molecular Regulatory E Enzyme IVDR/ CE Mark Complete Complete Complete Complete Complete HI 2023 H2 2022 H2 2022 H2 2023 Complete Complete HI 2023 lumiraDx™ Note: Regulatorytimelines refer to submission dates and launch dates and will be subject to review by corresponding regulatory authorities. Copyright ©2022 Lumirax Ltd. All Rights Reserved. Worldwide Expected FDA 510K H1 2023 H1 2023 HT 2023 H1 2023 H2 2022 HT 2023 H1 2023 HI JUZI H1 2023 H1 2023 H2 2023 H2 2022 TBC TBC H2 2023 WHO PQ H2 2023 H2 2022 H2 2023 H2 2023 H2 2023 H2 2023 H2 2022 Metabolic/Electrochemical 13#14Stjes diapa m SARS-CoV-2 Ag Ultra Saan Dany a hag Emak SARS-CoV-2 Ag Ultra Pool Platform Technology & Manufacturing SARS-CoV-2 Ab SARS-CoV-2 & RSV SARS-CoV-2 & Flu A/B HbAlc D-Dimer INR NT-proBNP Copyright ©2022 LuminaDx Ltd. All Rights Reserved. Worldwide CRP CemetatUiser Patient Test flosult Hiutday Settings Quality Control Logout Tumira Ex#15LumiraDx Platform Simplifies, Scales Down and Integrates Principles Used in Lab Systems Common Transduction Precise Fluidic Control No Sample Matrix Bias Non-Specific Binding Control Calibration Bias Assay Precision lumiraDx™ LumiraDx Platform Fluorescence / electrochemical Piezo bender/test strip bladder Gas wash / liquid-free image Particle coating / anti-hama Calibration to lab standard Materials, process, assay controls Central Lab System Fluorescence/ chemiluminescence Syringe pumps Multiple buffer washes Assay design/ anti-hama Calibration to lab standard Chemistry, assay controls Copyright © 2022 Lumirax Ltd. All Rights Reserved, Worldwide Chunky Remerent 20 lumirex handia O SAPS GOVER THAVE 15#16Our Platform Allows for Multiple Sample Types and Test Technologies on Common Strip Architecture Test Technologies Immunoassay Enzyme Molecular Sample Types Fingerstick blood Venous blood/ Plasma/Serum lumiraDx™ Clinical Chemistry Hematology Electrolytes / Blood Gas Nasal/Nasopharyngeal Throat Swab + Saliva Urine Copyright © 2022 LumiraDx Ltd. All Rights Reserved. Worldwide INR D-Dimer SARS COV-2 Ab SARS COV-2 Ag 16#17Sample 1 2 Sample Added 3 High Sensitivity at POC Driven by Microfluidic Immunofluorescence Technology Sample and Reagents Actively Mixed in Channels Active Fluidics Move Sample lumiraDx™ (4) Sandwich Assay Binding De 20 Assay Binding View Mag Particle Mag Fluorescent Latex Latex Magnet 5 Magnetic Field Captures Bound Particles Copyright © 2022 Lumirax Ltd. All Rights Reserved, Worldwide 6 Sample and Any Unbound Label Removed Using Air O4X Magnet 04x 8 Results Displayed Optical Reader Engine Magnet 7 Dry, Clear Fluorescent Signal Measured RESULTS IN MINUTES 17#18O Highly Scalable Manufacturing Enables Global Growth Strategy Test strips manufactured on a common platform using a high volume, web-based, automated manufacturing process Platform manufacturing facilities located in Alloa, Stirling, and Glasgow Scotland with total current capacity of over 28 million test strips per month with possibility to expand further Instrument manufactured by Flextronics (a contract manufacturer) at its facility in Althofen, Austria lumiraDx™ Copyright © 2022 LumiraDx Ltd. All Rights Reserved. Worldwide 18#19Simple, Common Strip Design Enables Low Cost and Disruptive Market Pricing 0.10 0.10 0.065 0.11 lumiraDx™ 06'0 010 0 THE 900 II!! 0000 Base Price Central Lab Copyright © 2022 Lumirax Ltd. All Rights Reserved, Worldwide Testing Prices* 2-3x Central Lab Lumira DX POC companyestimate 5-10x Central Lab Other POC 19#20lumiraDx™ IP Ring-Fence Model for POC Platform Manufacturing Assays Microfluidic Strip Instrument lumiraDx Platform Protected by issues and pending patents and know-how including: O 0 0 At least 15 U.S. patents At least 100 foreign patents 0 At least 5 pending PCT patent applications At least 50 pending foreign patent applications 2 pending U.S. provisional applications Copyright © 2002 Lumirax Ltd. All Rights Reserved. Worldwide 11 pending U.S. non-provisional patent applications 20#21Comprehensive Diagnostic Solutions from Lab to Home . Fast Lab Solutions Reference Labs Innovative qSTAR technology Single step method on open channel PCR systems • Results in 20 minutes D INA STAR Complete Up to 1000 tests/hour/machine * Authorized tests: COVID RNA STAR, COVID RNA STAR Complete, COVID & Flu RNA STAR Complete, COVID Dual Target RNA STAR Complete Pipeline areas: Respiratory, Sexual Health, Global Health, Virology lumiraDx™ = ■ # LumiraDx Platform **** POC Labs Ag LITE Actively controlled microfluidic technology Lab comparable performance at point of care Multiple technologies, sample types and tests on a single system Authorized tests: COVID antigen/antibody, D- Dimer, INR, CRP, HbA1c,NT-ProBNP Pipeline areas: Respiratory, Cardiovascular, Coagulation, Diabetes, Sexual Health, Global Health, Virology Decentralization Copyright © 2022 LumiraDx Ltd. All Rights Reserved. Worldwide amira COVID-19 Rail Tr · · W Antigen Home, Screening Venues PREME JE - SAUNIE cone 19 www www Actively controlled microfluidic technology Lab comparable performance at point of need, designed for the home Authorized tests: COVID antigen (POC) Pipeline areas: Chronic disease management, global health screening 21#22SAREEMEENT SARS-CoV-2 Ag Ultra Platform Strategy and Pipeline KARD-CAFE AS SARS-CoV-2 Ag Ultra Pool SARS-CoV-2 SARS-CoV-2 SARS-CoV-2 Ab & RSV & Flu A/B B HbAlc D-Dimer INR NT-proBNP Copyright © 2022 LuminaDx Ltd. All Rights Reserved, Worldwide CRP General User Patient Test Result History Settings Quality Control Logout lumiraDx#23Platform Strategy Focused on Improving and Expanding the POC Testing Experience 1 2 3 lumiraDx™ Raise the standard for POC testing performance, speed, access and experience Consolidate multiple POC instruments to a single lab comparable platform Develop comprehensive test menus by disease and care setting Copyright © 2022 LumiraDx Ltd. All Rights Reserved. Worldwide 23#241 Raise the Standard for POC Testing Performance, Speed, Access and Experience High sensitivity and speed: ULTRA product line delivers high sensitivity results for respiratory disease diagnosis, taking test times from 15-30 minutes down to 5 minutes Easy sample collection: Only quantitative fingerstick blood-based tests for D-Dimer and NT- proBNP to aid faster clinical decisions in community settings Built to expand access: Portable system (2.2 lbs, low footprint, battery operated, room temp reagents) and cloud-based connectivity enables centrally managed program in the community lumiraDx™ 500 0 Example: Rule of Venous Thromboembolism with LumiraDx D-Dimer test 0 500 LumiraDx µg/L FEU Copyright © 2022 LumiraDx Ltd. All Rights Reserved. Worldwide 1000 1000 15:00 ROOD 2:00 2000 500 Method Comparison 1000 1500 2000 2500 3000 3500 400 bioMérieux Vidas pg/L FEU 100% negative predictive value at the 500 µg/L cut off, when used in combination with a pretest probability score Fingerstick sample, results in 6 minutes Strong correlation with the laboratory reference, in particular around the clinically relevant values of <750 µg/L FEU 24#251 0 HÀ HÀNG 12, HÀNH TRÌNH HOẠT ● Real World Evidence Supports LumiraDx COVID Antigen Test Molecular-Like Performance Analysis inclusive of >680,000 test results from Avera McKennan Hospital & University Health Center Sensitivity of LumiraDx microfluidic test similar to PCR in asymptomatic and symptomatic individuals, higher than lateral flow tests WyPy Rae by Tent Method-We Rolling Ag lumiraDx™ Bea De LOW -3 POR FE OPOC -44 Wkly Poly Rae by Tea Metod - 4 Wok Roding Arge maiti Copyright © 2020 Lumiax Ltd. All Rights Reserved, Worldwide FARETAGETH LEW PCR P#261 Introducing High Sensitivity Respiratory Testing with Ultra => Results in 5 minutes TH SARS-COV-2 Ag Ultra lumiraDx™ O High sensitivity: COVID Ultra PPA 97.4% at Ct <34 Fast results: 5 minutes from sample application Full respiratory pipeline: COVID, Flu A/B, RSV, Strep A Grouping Ct < 34 (all) Ct < 33 (all) Ct < 30 (all) Ct < 25 (all) N 39 38 35 25 Copyright © 2022 LumiraDx Ltd. All Rights Reserved. Worldwide PPA 97.4% 97.4% 97.1% 100% 26#271 Unmet Need for High Sensitivity Troponin POC Test with a $900M Addressable Market(1) Intended Use Regulatory Authorization LOQ Clinical Sensitivity Reportable Range Sample Size Sample Type Time to Result lumiraDx™ True POC Needs Aids in diagnosis of MI CE Mark, FDA 510K s2.0 ng/L I Whole blood (2h): 90% + 2.0 – 1,000 ng/L 20μL direct fingerstick | Capillary WB, venous blood, plasma ≤10 min Lab Reference Abbott Architect STAT hs-Tnl* Aids in diagnosis of MI CE Mark, FDA 510K ≤3.2 ng/L (specification) 1.5-2.9 ng/L (observed) EDTA Plasma (2-4h): 90.9% 3.2 – 50,000 ng/L 210 µL (on-board) 10 μL (manual dilution) Plasma & serum (LiHep, EDTA) 18 min (time to first result) POC Example Siemens Atellica VTLi hs-cTnl* Aids in diagnosis of MI CE Mark 2.1 ng/L plasma 3.7 ng/L - WB Whole blood (2h): 81.3% 2.1 (plasma)/3.7 (WB) - 1,250 ng/L 30-100 µL Capillary WB, venous WB & plasma (LiHep) Copyright © 2022 Luminox Ltd. All Rights Reserved, Worldwide 8 min (1) Based on our current assumptions, including (a) the existing market sizes, (b) central lab market that could move to POC, and (c) expansion of diagnostic testing. (2) Based on respective company product specifications. POC Example Triage True hsTnl(2) Aids in diagnosis of MI CE Mark 2.1-3.6 ng/L - plasma 2.8 ng/L - WB EDTA Plasma (2-4h): 91.9% 0.1 – 1,000 ng/L 175 µL Venous WB & plasma (EDTA) 20 min Key differentiator 27#281 LumiraDx Troponin (pg/mL) 16.0 14.0 12.0 10.0 8.0 6.0 4.0 2.0 0.0 -2.0 lumiraDx™ 2 Feasibility of High Sensitivity Troponin Results at POC LumiraDx Plasma Troponin vs Architect 4 6 8 10 y = 0.9544x+0.0377 R² = 0.9868 Mean Architect Troponin (pg/mL) 12 14 Copyright © 2022 LumiraDx Ltd. All Rights Reserved. Worldwide 16 Precision Troponin (pg/mL) 1.1 8.2 19.5 CV % 25 7.4 6.6 N 12 34 36 28#291 Key Targets and Workflow 98% sensitivity No culture confirmation Results in 8 minutes, with early call out starting 3 minutes 0 Fluorescence (R) Performance Feasibility D1 (1:20) m wood L 40000 bode 10000 E Strep A Molecular Program Demonstrates Feasibility to Achieve Target Sensitivity Group A Strep H M Cycles lumiraDx™ Fluorescence (R 0000 KOKK 20000 1 . IN D2 (1:200) Group A Strep I E Cycles 1 H Fluorescence(R) 10000 30000 # Sample Collection & Lysis D3 (1:2000) N D Group A Strep M 15 . - Fluorescence (8) ocol 24 Insert Strip & Add Sample D4 (1:20000) Group A Strep Copyright ©2020 Lumirax Ltd. All Rights Reserved. Worldwide D P Cycles 21 Dilution D1 (1:10¹) D2 (1:10²) D3 (1:10³) D4 (1:104) D5 (1:105) D6 (1:106) D7 (1:107) |||| Amplification LMDX qSTAR 8/8 8/8 8/8 8/8 0/8 0/8 0/8 On market POC MDX 3/3 3/3 3/3 2/3 0/3 0/3 0/3#301 TB Molecular Program Demonstrates Feasibility to Develop Swab Based POC Test Key Targets and Workflow Tongue swab sample Results in 20 minutes Access to testing for HIV+ and Pediatric Populations, currently underserved Performance Feasibility Copy number (cp/rxn) 11 5.6 1.3 0.6 lumiraDx™ No of positives 8/8 8/8 33/38 3/8 % positivity 100 100 87 33 Value Proposition POC TB test has opportunity to increase patients linked to care Number of patients at each step of cascade 5,000,000 4,500,000 4,000,000 3,500,000 3,000,000 2,500,000 2,000,000 1,500,000 1,000,000 500,000 0 2,840,000 100% Individuals with incident TB 1,938,027 Copyright © 2020 Lumiax Ltd. All Rights Reserved, Worldwide Accessed TB 1,629,906 57% 1,417.838 50% 1,221,764 Diagnosed with TB Registered in treatment TB Care Cascade in Indian Public Health System 43% B Treatment success 1,049,237 37% Recurrence-free survival#311 LumiraDx Platform Offers the Benefits of POC Testing with the Accuracy of Laboratory Testing 10 SARS-CoV-2 Ag Ultra SARS-CoV-2 Ag Ultra Pool lumiraDx™ Prep Sample Ö SARS-CoV-2 SARS-CoV-2 Ab & RSV 1 Minute SARS-CoV-2 & Flu A/B HbA1c (> D-Dimer Load & Run INR NT-proBNP Copyright © 2022 LumiraDx Ltd. All Rights Reserved. Worldwide Report Results CRP 2-12 Minutes LumiraDx solutions combine common assay types all in one instrument (IA, clin chem, molecular, and enzyme); reduce costs and simplify workflow A single scalable platform to complete a wide range of popular POC tests Patient receives accurate results in minutes Low-cost of ownership Diagnosis and Treatment Selection 31#322 Consolidate Multiple POC Instruments to a Single Lab Comparable Platform ххх X Respiratory Immunoassay Coagulation Diabetes, Inflammation NEAR TERM Able to move most European customers from 3 → 1 Platform with INR, COVID Ag, Flu A/B, RSV, CRP and HbA1c lumiraDx™ Respiratory Molecular Diabetes, Cardiovascular Copyright © 2022 Lumirax Ltd. All Rights Reserved, Worldwide Cardiac, Blood gas, Metabolic 18-24 MONTHS Able to move most US and European customers 6 → 1 Platform with US authorizations and addition of molecular respiratory, lipids, electrolytes, and cardiac content 32#332 Coagulation Diabetes Inflammation Respiratory INR D-Dimer HbA1c Creatinine CRP |Procalcitonin COVID Ultra COVID&Flu Cardiovascular NT-proBNP Troponin Total GP Revenue Total LumiraDx Revenue 1200 600 Builds Broad Testing Menu and Volumes Per Customer Illustrative YEAR 1 Volume Reimbursement (€) 600 120 1800 60 5.29 5.76 5.19 2.49 Illustration: Germany GP Office Group Total GP and LumiraDx Revenue Per Year 21.71 Illustrative YEAR 2 Revenue (€) Volume Reimbursement (€) 600 120 1800 € 3,171 € 691 € 9,338 € 2,994 € 1,303 € 17,497 € 10,180 1200 120 450 150 120 240 5.29 5.76 5.19 2.49 12.29 21.71 12.04 Revenue (€) € 3,171 € 691 € 9,338 Copyright © 2022 Lumirax Ltd. All Rights Reserved, Worldwide € 2,994 € 1,474 € 2,605 € 2,889 € 23,163 € 11,070 Illustrative YEAR 2 Volume Reimbursement (€) 600 120 1800 480 1200 240 300 300 240 240 5.29 5.76 5.19 0.66 2.49 12.29 21.71 12.04 Revenue (€) € 3,171 € 691 € 9,338 € 317 € 2,994 € 2,948 € 5,211 € 2,889 € 27,559 € 12,660 Note: Represents a disruptive pricing strategy to enable rapid adoption of multiple parameters on the instrument, with $20K revenue per instrument for the GP office in Year 1. Illustrative numbers are not projections; they are goals and are forward-looking, subject to significant business, economic, regulatory and competitive uncertainties and contingencies, many of which are beyond the control of the Company and its management and are based upon assumptions with respect to future decisions, which are subject to change. Actual results will vary and those variations may be material. 33 lumiraDx™#343 Application TAM* POC Specifications Commercial Status* lumiraDx™ Significant Progress in Meeting Community Based Testing Needs lumiraDx CRP ww Antimicrobial stewardship $300M Fingerstick sample, results in 4 min Commercially Available lumiraDx D-Dimer Rule out of Venous Thromboembolism $700M Fingerstick sample, results in 6 min Commercially Available lumniraDx INR Coagulation monitoring $500M Fingerstick sample, results in 1 min Commercially Available lumiraDx NT-proBNP Heart Failure diagnosis $350M Fingerstick sample, results in 12 min CE Mark Expected H2 2022 Launch lumiraDx HbAlc Diabetes screening & monitoring $1.3B www Fingerstick sample, results in 7 min CE Mark Expected H2 2022 Launch * Global Total Addressable Market: We estimated for each test based on our current assumptions, including the (a) existing market sizes, (b) central lab market that could move to the POC, and (c) expansion of diagnostic testing. Copyright © 2022 LumiraDx Ltd. All Rights Reserved. Worldwide#353 Respiratory Coagulation Disease Area and Test Diabetes Global Health Inflammation lumiraDx™ COVID Ultra CRP Flu A/B Ultra RSV Ultra Strep A INR Cardiovascular BNP D-Dimer NT-ProBNP 2022 2023 Pipeline Plan HS Troponin Na/K Lipids HbAlc TB HIV Viral Load CRP Focacifonin Concept Qual Immunoassay Feasibility Development Quant Immunoassay Verification & Validation Copyright © 2022 LumiraDx Ltd. All Rights Reserved. Worldwide Molecular Regulatory E Enzyme Planned Submissions IVDR/ CE Mark Complete Complete Complete Complete Complete H1 2073 H2 2022 H2 2022 H2 2023 Complete Complete H1 2023 Note: Regulatory timelines refer to submission dates and launch dates will be subject to review by corresponding regulatory authorities. Expected FDA 510K H1 223 H1 2023 H1123 HT 2023 H2 2022 H1 2023 HI 2023 H1 2023 HV 2023 Hi 2023 H2 2023 H2 2022 TBC TBC H2 2023 WHO PQ H2 2023 H2 2022 H2 2023 H2 2023 H2 2023 H2 2023 H2 2022 Metabolic/Electrochemical 35#363 Respiratory Immunoassay COVID Ag COVID Ab Flu A/B RSV CRP sPneumo Legionella Respiratory Molecular COVID Flu A/B RSV Strep A TB Qual Immunoassay lumiraDx™ Develop Comprehensive Test Menus By Disease and Care Setting Cardiovascular Troponin D-Dimer BNP NT-ProBNP Lipids ALT/AST Na/K/Ca hsCRP Blood Gases Sexual Health Molecular CT/NG Syphilis HCV HBV HIV Quant Immunoassay Coagulation INR D-Dimer Creatinine Sexual Health Immunoassay HIV HCV HBV Syphilis Molecular Diabetes/Kidney Copyright ©2022 Lumirax Ltd. All Rights Reserved. Worldwide HbA1c Glucose Creatinine ACR TSH T4 Free T3 Wellness & Other Vitamin D PIGF PSA bHCG Sickle Cell Anemia Enzyme Sepsis Procalcitonin Lactate MRSA Toxicology Opiates Meth/Amphetamines Barbiturates Benzodiazepines Cocaine Methandone * Items marked in bold are the diagnostic tests for which we have obtained regulatory approval, authorization, certification or clearance for use on our Platform Metabolic/Electrochemical 36#37Leveraging our Technology Beyond the Platform: Diagnostic Solutions From Lab to Home SARS-CoV-2 Ag Ultra SARS-CoV-2 Ag Ultra Pool SARS-CoV-2 Ab SARS-CoV-2 & RSV SARS-CoV-2 & Flu A/B HbAlc D-Dimer INR NT-proBNP Copyright ©2022 Lumirax Ltd. All Rights Reserved. Worldwide CRP MARE General User Setting Patient Test Result History FOOL Quality Control Logout lumira Dx#38125 100 75 50 25 Our Extended Portfolio Targets the Global IVD Market Across Sectors We have been able to leverage our technology and manufacturing expertise to directly serve the lab and self-testing segments LumiraDx Targets the Global IVD Market ($B) Platform Focus 12 POC Professional Testing lumiraDx™ RNA Star Lab Test 64 Central Lab 28 Amira Self Test COVID 13 Source: Industry reports, companyestimates Self Testing 117 Total Copyright ©2022 Lumirax Ltd. All Rights Reserved. Worldwide Commentary LumiraDx has developed a unique offering capable addressing the global IVD market: The Platform i. improves POC professional testing, and ii. will allow transition of some lab-based test to the point of care The RNA Star Lab Test improves PCR speed and efficiency for Central Lab test The Amira System leverages the technology of our Platform to serve the Self Testing segment 38#39COVID Example: Comprehensive Portfolio from Lab to Home RNA STAR Open Molecular Systems SA Compl 6 INA STAR Reference Labs Innovative qSTAR technology Single step method on open channel PCR systems Ⓒ Results in 20 minutes Up to 1000 tests/hour/machine Indications for asymptomatic, pooling and sample home collection lumiraDx™ • Detects omicron with equivalent sensitivity to other variants Antigen/Antibody LumiraDx Platform 1000 SUSCINE Ab 101 LASA POC Labs Microfluidic technology High sensitivity antigen test: Ⓒ 97.6% PPA with RT-PCR up to 12 DSO Ⓒ Effectively detects VOCS • Detects Omicron with equivalent sensitivity to other variants Ⓒ 5 min COVID Ultra achieved CE Mark, Europe launch in Q3(2) Antigen Pool(1) LumiraDx Platform PumunoDx POOL TEST SARS-COM-2 Ag Professional-Led Screening • Microfluidic technology Enables pooling of 5 samples on a single test strip, with high sensitivity High throughput at low cost Pooling and deconvolution on single POC Platform Detects Omicron with equivalent sensitivity to other variants Decentralization (1) LumiraDx SARS-CoV-2 Antigen Pool and Amira POC test are available under CE Mark only; not available in the US. (2) COVID Ultra in development for US market and subject to FDA review. Copyright ©2022 Lumirax Ltd. All Rights Reserved. Worldwide Antigen Amira System(1) amira COVID-19 T meng Haders Mod (comezabal BREATED Ragg Home/Consumer Venues Microfluidic technology High sensitivity, low cost. connected antigen test Screening and self-test applications Ⓒ Amira POC test achieved CE Mark 39#40O qSTAR Technology Revolutionizes Molecular Testing in the Lab and at POC O Proprietary STAR technology delivers high speed AND high sensitivity reagents O Fast Lab Solutions Current and Future offerings Run on open channel RT-PCR instruments 20 min time to result on PCR analyzers - A revolution in lab turnaround time and scalability FDA EUA obtained for RNA-STAR COMPLETE for COVID CE Mark affixed to RNA STAR Complete for COVID as well as COVID & Flu combo Established research assays for RSV, Strep A, TB, HIV, HBV, HCV, CT, NG, TV lumiraDx™ Saturda DOFTULTS (1) Each van fits two instruments for increased throughput with 1000 tests/hour/instrument Copyright © 2022 LumiraDx Ltd. All Rights Reserved. Worldwide Scalable and Accessible Mobile Collection and Testing Delivers 2,000 results per hour¹, offering high sensitivity, high throughput and affordable testing to cruise lines, events, universities, etc. Growing Regional Fast Lab Network Over 100 accredited PCR labs already use our Fast Lab technology on open PCR systems to rapidly report critical COVID results Developing Pipeline for POC Platform Fast Lab Solutions reagents in development may be rapidly adapted to the POC Platform 40#41F Amira Has Broad Screening and Home Testing Capabilities Amira Analyzer amira COVID - 19 2+ Amira Test Strip and Carton under 20 minutes Suitable for ages 2+ years luminaDx 30 lumiraDx™ HER SMARTPHON WE THRILY WITH KERETA Detalls and may dunes and amp A Tada par - SP COVID-19 50 TESTS $2-4 COVID-19 Antigen Test for POC and OTC(1) insert Strip Apply Sample Close Door Wait-Processing 00000 Screening and Diagnosis High sensitivity, connected screening for infectious diseases: 0 Respiratory, HIV, Malaria LumiraDx Engage App Copyright ©2022 Lumirax Ltd. All Rights Reserved. Worldwide E Wellness and Chronic Disease Management At-home monitoring of chronic conditions as well as OTC testing solutions (1) Anticipated retail price per test. Amira COVID Ag test has CE Mark for POC use. All other applications in various stages of development. 41#42Designed to Enable Home Based Connected Care Across Many Applications Abnormal test result Telemedicine visit with provider www b S 0000CD ong Amira home device conducts test lumiraDx Follow up test to ensure medication effectiveness Online pharmacy delivers medication to home lumiraDx™ Source: CDC; company estimates Normal test result Virtual Assistant orders medication refill Copyright © 2022 LumiraDx Ltd. All Rights Reserved. Worldwide Patient Profile Diabetes Fertility Wellness Current and Potential Tests HbA1c Glucose Ur Albumin Ur Creatinine LH Estradiol Progesterone HcG Ketones Vitamin D Iron US Patients 37M 3.6M 5M 26M 10M 42#43SAREEMEENT SARS-CoV-2 Ag Ultra Commercial Strategy and Customer Stories KARD-CAFE AS SARS-CoV-2 Ag Ultra Pool SARS-CoV-2 Ab SARS-CoV-2 & RSV SARS-CoV-2 & Flu A/B B HbAlc D-Dimer INR NT-proBNP Copyright © 2022 LuminaDx Ltd. All Rights Reserved, Worldwide CRP General User Patient Test Result History Settings Quality Control Logout lumiraDx#44Global Commercial Footprint and Platform Placements to Drive Penetration of TAM* 200+ commercial employees located in 27 countries Direct sales operations in Western Europe, USA, Japan, Colombia, Brazil, India and Africa. Distribution in another >30 countries. Total reach: 105 countries Over time, plan to operate with a direct commercial presence in each of the largest diagnostics markets, including China, South Korea, Southeast Asia and Latin America to ensure broad access of our Platform globally lumiraDx™ "as of March 2022 Copyright © 2022 LumiraDx Ltd. All Rights Reserved. Worldwide Instrument Placement Locations 44#45Instruments shipped (1) Strategic Partner Key Products(2) lumiraDx™ Customer Focused Growth Strategy Near-Term Opportunities Physician Office / Pharmacy ♥CVS pharmacy 8,500+ US and Global Health Systems Boots COVID Antigen / Ultra √ Flu A/B + COVID √ RSV + COVID-19 √ Strep A Molecular CRP √ HbA1c √ INR √ Na/K Lipids D-Dimer NT-proBNP Acute / Emergency Care 5,400+ NHS HS Troponin BNP D-Dimer √ NT-proBNP COVID Antigen / Ultra √ Flu A/B + COVID √ RSV + COVID-19 √ Procalcitonin Global Health Copyright ©2022 Lumirax Ltd. All Rights Reserved. Worldwide 5, 100+ BILL MELINDA GATES foundation TB Molecular HIV Viral Load COVID Antigen / Ultra CRP √ D-Dimer √ INR √ HbA1c √ (1) Total instrumentshipments are 25,000+ with 6,000+ estimated for use in COVID screening applications with future testing needs to be determined (2) Tests critical to launch in customer segmentare bolded; tests with regulatoryauthorization in initial market, and currently commercially available or planned to be available in H2 2022, are checked 45#46Number of LumiraDx Instruments within Health System Use cases POL Urgent care Pharmacy Hospital lab Reference lab Surgery West Coast Health System: Small Start, Big Finish lumiraDx™ 125 Q3 2021 158 Q4 2021 402 Q1 2022 422 Q2 2022 Case Study Multiple COVID testing solutions established early in the pandemic High interest in LumiraDx microfluidic technology led to initial partnership Initial Physician Office focused program expanded to replace all existing POC molecular systems • Performance comparable to POC molecular system Ⓒ San Diego R&D visit strengthened interest in future pipeline • Manufacturing and supply capabilities in Q4 to provide uninterrupted supply Copyright © 2022 Lumirax Ltd. All Rights Reserved, Worldwide "Grateful for the support and partnership, LumiraDx agility has been great" Director of Sourcing Laboratory Services 46#47Implementation of POC INR Solution in UK Siloed, practice-based system with their own practice leads, nurses, platforms, locations and patients resulting in inefficiencies in staffing 0000 000 - 10000 L 1000 - - - DOD GO 0000 - DOD Each practice has their own backend and overhead, leading to operational inefficiencies lumiraDx™ Source: Internal Intrahealth TTR data Connected, streamlined, and integrated system with fewer practice leads, all nurses use the same platform and perform targeted testing at many settings to improve patient experience Org Redesign lumiraDX INRstar Copyright © 2022 LumiraDx Ltd. All Rights Reserved. Worldwide 0 Case Study DOO DOD Reduced overhead with fewer Practice Leads, Nurses, Locations, and Instruments 47#48Southern Sweden Region: Performance Enables Novel Testing Opportunities and Use Cases Previous challenges with D-Dimer testing Thromboembolic conditions are a leading cause of death, may be ruled out with D-Dimer test Rapid D-Dimer testing program in Kalmar region discontinued High level of false positive results Patient stress and unnecessary hospital admissions lumiraDx™ LumiraDx program LumiraDx Platform evaluated and selected for POC testing Lab comparable performance Fingerstick blood sample Portable, fast, reliable, and easy to use at point of care Testing implemented at 24 sites, GP offices Portability Mobile team opportunity = Copyright © 2022 LumiraDx Ltd. All Rights Reserved. Worldwide Future plans and opportunities Fingerstick sampling enables expansion of POC and new use cases for D-Dimer Portability for mobile teams, emergency dept, and ambulance Range of analytes, Troponin, CRP, increase customer value Correct and rapid test results lead to better outcomes and overall lower costs Case Study Connectivity efficiency in admin of results, operators, etc. 48#49SAREEMEENT SARS-CoV-2 Ag Ultra KARD-CAFE AS SARS-CoV-2 Ag Ultra Pool Company Profile & 2025 Outlook SARS-CoV-2 Ab SARS-CoV-2 & RSV SARS-CoV-2 & Flu A/B B HbAlc D-Dimer INR NT-proBNP Copyright ©2022 Lumirax Ltd. All Rights Reserved. Worldwide CRP General User Patient Test Result History Settings Quality Control Logout lumiraDx#50lumiraDx™ LumiraDx Key Building Blocks Blockbuster Product: HS Troponin 20%-25% of Total Revenue Cardiovascular Represents >$1 billion run-rate revenue (Q4 2025 projected ryn-rate) Blockbuster Product: HbA1c 10%-15% Diabetes 10% Coagulation Blockbuster Product: Flu, COVID, Strep A 20%-25% Respiratory 10% Inflammation Copyright © 2022 LumiraDx Ltd. All Rights Reserved. Worldwide 5% Global Health 10%-25% Other 50#51Cumulative instruments shipped Test strip manufacturing capacity / month Countries served Total Revenue Platform Revenue Fast Lab Solutions Other revenues lumiraDx™ (1) Unaudited financials Financial Profile 2019 -200 4 Million 6 $23M $0.2M $23M 2020 -8,000 16 Million 27 $139M $111M $1M $27M Copyright © 2022 LumiraDx Ltd. All Rights Reserved. Worldwide. 2021 -21,000 28 Million 98 $421 M $344M $41M $36M YTD Q2 20221 -25,000 28 Million 105 $171M $111M $48M $12M 51#52LumiraDx Today: Transforming Community-based Healthcare Next Generation POC Diagnostic Company Addressing the current limitations of legacy POC systems by bringing lab-comparable performance to the POC in minutes, a broad menu of tests on a single instrument, and a low cost of ownership Large Installed Base with Global Commercial Reach Manufacturing Designed for Scale Broad Menu and Pipeline of Diagnostic Tests Experienced Management Team lumiraDx™ 25,000 instruments shipped to 105 countries across primary care, pharmacy, hospital emergency departments, global health, and other settings . All current and future POC tests are developed on common strip design, enabling flexible, automated and low-cost manufacturing on a single line. Current manufacturing capacity of 28 million test strips per month Regulatory clearance for 12 tests for use on our Platform, with global TAM of $5B+ (excluding COVID). 50+ assays in three-year roadmap* Fourth POC company for founding team. Management team has a successful track record of diagnostic innovation and building / scaling companies in POC Global Total Addressable Market: We estimate each test based on our current assumptions, including (a) the existing marketsizes. (b) central lab market that could move to POC; and (c) expansion of diagnostic testing. Copyright ©2022 Lumirax Ltd. All Rights Reserved. Worldwide 52#53SAREEMEENT SARS-CoV-2 Ag Ultra KARD-CAFE AS SARS-CoV-2 Ag Ultra Pool SARS-CoV-2 Ab Appendix SARS-CoV-2 & RSV SARS-CoV-2 & Flu A/B B HbAlc D-Dimer INR NT-proBNP Copyright ©2022 Lumirax Ltd. All Rights Reserved. Worldwide CRP General User Patient Test Result History Settings Quality Control Logout lumiraDx#54Point of Care Testing is Being Adopted Worldwide Western World Adoption: A Push Towards Community Care United States A push towards community based services is at the top of Biden's healthcare agenda with $400bn in Medicaid funding to expand access to home and community based services¹ United Kingdom: NHS is leading the path in Europe In 2019 the NHS outlined its five year plan to move to a new service model for the NHS, setting out five changes required: 1 Boost "out of hospital care" 2 Redesign and reduce pressure on emergency hospital services 3 Deliver more personalised care Digitally enable primary and outpatient care 5 Local NHS organisations to focus on population health To support this the NHS committed £13bn to community pharmacy's confirming their future as an integral part of the NHS² lumiraDx™ Global Health Adoption of POCT (³) POCT improves patient care, especially in re-source limited settings where laboratory infrastructure is poor and patients predominantly live in rural settings UNAIDS launched the Diagnostics Access Initiative, to ensure increased access to quality diagnosis so people with HIV can be effectively linked to quality treatment services The WHO recognises the importance that quality-assured POCT will play in the success of global health programs A study assessing the impact of POCT in Global Health disease programs found that: POCT in HIV resulted in a 20 fold increased uptake and coverage and increased status and awareness from an average of 6% to 20% In tuberculosis, a study found POCT in communities resulted in a 49% increased detection rate of tuberculosis (1) White House Infrastructure Bill 2021 (2) NHS England Long Term Plan 2019; (3) Peter N. Fonjungo, Debrah I. Boeras, Clement Zeh, Heather Alexander, Bharat S. Parekh, John N. Nkengasong, Access and Quality of HIV-Related Point-of-Care Diagnostic Testing in Global Health Programs, Clinical Infectious Diseases, Copyright ©2022 LuminaDx Ltd. All Rights Reserved. Worldwide 54#55lumiraDx™ Copyright © 2032 Luminox Ltd. All Rights Reserved. Worldwide.